Search Results
Your search for ,HOW matches 8288 pages
Showing 2451 - 2500Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer
There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however, investigators recently assembled an expert panel to help fill this void. In a study published by Emily Johnston, MD, MS, and colleagues in the journal...
Expanding Role of Liquid Biopsies in Cancer Detection and Therapeutics: Now and in the Near Future
“It is possible that within the next several years, perhaps 75% of cancers can be detected by screening,” Bert Vogelstein, MD, PhD, projected at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care.1 “I anticipate that perhaps 50% of cancers can be detected...
Imaging Study Aims to Detect Rates of Cancer in Medieval Britain
The first study to use x-rays and computed tomography (CT) to detect evidence of cancer among the skeletal remains of a preindustrial population suggests that between 9% to 14% of adults in medieval Britain had the disease at the time of their death. These findings were published by Mitchell et al...
Fertility Concerns May Influence Decisions About Endocrine Therapy in Young Women With Breast Cancer
Concerns about fertility often influence how young women with breast cancer approach treatment decisions and are a reason for forgoing or delaying hormone-blocking therapy, according to findings from a recent study published by Sella et al in the journal Cancer. The findings reinforce the need for...
YouTube Videos on Bladder Cancer: Study Focuses on Quality of Content
Social media platforms are valuable tools for educating patients about serious health topics, but they can also spread false and biased information with potentially harmful results, according to recent research published by Stacy Loeb, MD, MSc, and colleagues in European Urology. Researchers...
Platinum-Sensitive Recurrent Ovarian Cancer
Ursula Matulonis, MD; Joyce F. Liu, MD, MPH; and Bobbie J. Rimel, MD, discuss a case of a woman with platinum-sensitive recurrent ovarian cancer who was found to have a germline BRCA1 mutation. They address the question of how to choose the optimal chemotherapy regimen for patients who are...
Hormonal Intrauterine Device Under Study for Managing Early Endometrial Cancer
Disease regression was observed in 82% of women with endometrial hyperplasia with atypia and 43% of women with endometrial cancer after treatment for 6 months with a hormonal intrauterine device in a phase II study reported during the virtual edition of the Society of Gynecologic Oncology (SGO)...
Chernobyl at 35 Years: An Oncologist’s Perspective
Editor’s note: Dr. Gale is an authority on medical response to nuclear and radiation accidents and participated in rescue efforts at the Chernobyl disaster, as well as at Goiania, Tokaimura, and Fukushima, among other radiation and nuclear accidents. Anyone reading the popular press or even...
AACR and The Mark Foundation for Cancer Research Announce New Grants
The American Association for Cancer Research (AACR) and The Mark Foundation for Cancer Research recently announced five grants to support innovative research focused on understanding the influence of a patient’s biology on the genesis, development, treatment, and survivorship of cancer. Each...
Turning Confusion Into Clarity: Lessons Learned From Autism Spectrum Disorder
Autism spectrum disorder refers to a group of conditions characterized by difficulty in navigating normal social situations and having all-absorbing repetitive behaviors or stereotyped interests. At the milder end of the spectrum is Asperger’s syndrome, generally confined to people with higher...
How Interested Are Patients in Integrative Therapies, and How Much Are They Willing to Pay for Them?
The top two barriers to accessing complementary and integrative therapies, according to a survey of 576 patients with cancer and caregivers, were cost, cited by 56%, and a lack of knowledge about the therapies, cited by 52.1%. “Other barriers included a lack of time (29.2%), location of the...
Grateful to Be Alive
Everything about my breast cancer diagnosis, from my presentation to diagnosis, was strange. In the spring of 2006, I was performing my monthly breast self-exam when I felt a hard lump in the upper left quadrant of my left breast. Having lost a good friend to breast cancer 4 years earlier, I was...
Umbralisib for Previously Treated Relapsed or Refractory Marginal Zone Lymphoma and Follicular Lymphoma
On February 5, 2021, umbralisib was granted accelerated approval for the following indications: adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti–CD20-based regimen and adult patients with relapsed or refractory follicular lymphoma who have...
Ethical Considerations Before Launching a Clinical Cancer Trial
Randomized clinical trials are highly regulated initiatives that must comply with multiple requirements while maintaining high epistemic standards, a balance that becomes increasingly difficult as the research questions surrounding immunotherapy and targeted agents become more complex. To shed...
A Physician-Scientist’s Mother, Who Nursed Those With Chronic Diseases, Fueled His Passion for Biomedical Research
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Griffin P. Rodgers, MD, MACP, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Dr. Rodgers, a physician-scientist,...
Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma
On February 9, 2021, cemiplimab-rwlc was granted regular approval for the treatment of patients with locally advanced basal cell carcinoma (BCC) who were previously treated with a Hedgehog pathway inhibitor or for whom this type of therapy is not appropriate and granted accelerated approval for...
Improvement Programs to Optimize Patient Care for Black Americans With Breast Cancer
Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and White Americans have been selected to participate in ASCO’s quality programs, including the Quality Oncology Practice Initiative (QOPI®)and Quality Training Program...
Addressing Oncologist Burnout, Emotional Well-Being, and Moral Distress in the Pandemic
JCO Oncology Practice recently published an editorial that examines the intensified burnout oncology practitioners are experiencing due the COVID-19 pandemic and outlines critical interventions to support oncologists now and throughout a long-term recovery.1 The article was written by past,...
New ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment
ASCO has released a new guideline regarding the use of neoadjuvant chemotherapy, endocrine therapy, and targeted therapy in breast cancer.1 “This is the first time ASCO has embarked on a guideline for neoadjuvant therapy,” said Larissa A. Korde, MD, of the National Cancer Institute, and guideline...
Expert Point of View: Aaron T. Gerds, MD, MS
Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office, found the MANIFEST-2 findings to be highly noteworthy. He cited a...
Effect of Genomic Prostate Score Testing on Choice of Active Surveillance in a Predominantly Black Patient Population
In the ENACT study, reported in the Journal of Clinical Oncology, Murphy et al found that use of the 12-gene Genomic Prostate Score (GPS) in a predominantly Black patient population with relatively low-risk prostate cancer tended to be associated with reduced selection of active...
Immune Checkpoint Inhibitors and Cutaneous Toxicity: Population-Level Analysis
Immune checkpoint inhibitors have transformed treatment for many advanced cancers, but short-term clinical trials and small observational studies have linked the medications with various side effects, most commonly involving the skin. A more comprehensive, population-level analysis now provides a...
Acute Myeloid Leukemia World Awareness Day 2021: April 21
After a great response to Acute Myeloid Leukemia World Awareness Day (AML WAD) in 2020, Know AML looks forward to commemorating AML WAD in 2021. AML WAD will take place on April 21, 2021, with the aim to facilitate and improve knowledge of AML worldwide through collaborative participation. Know AML ...
To Advance Health Equity, Put Real-World Cancer Data to Work
Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons—like institutional racism and poverty—are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health...
FDA Pipeline: Recent Designations in Urothelial Cancer, Cervical Cancer, Cholangiocarcinoma, and More
Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for urothelial cancer, cervical cancer, cholangiocarcinoma, solid tumors, and colorectal cancer. Acceptance of Two Supplemental Biologics License Applications for Enfortumab Vedotin-ejfv in...
Recent Studies Explore Efficacy of COVID-19 Vaccination in Patients With Leukemia and Myeloma
Two new studies published in the journal Blood suggest that the BNT162b2 mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma. According to researchers, these studies could help inform the ideal time for vaccination of these...
Jeanne Tie, MD, MBChB, on Circulating Tumor DNA, Minimal Residual Disease, and Adjuvant Treatment
Jeanne Tie, MD, MBChB, of the Peter MacCallum Cancer Centre, discusses how to improve the current, somewhat imprecise, approach based on pathologic staging alone, used to select patients for adjuvant treatment. Circulating tumor DNA analysis after curative-intent treatment may detect minimal...
New Study Finds Baseline Brain Imaging Should Be Considered for Patients With Metastatic RCC
A report published by Kotecha et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests that baseline brain imaging should be considered in most patients with metastatic renal cell carcinoma (RCC). Researchers found incidental brain metastases occur in a clinically significant...
Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize different types of head and neck cancers, primarily those that are human...
Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care
Carey K. Anders, MD, of the Duke Cancer Center, discusses the ways in which treatment of brain metastases arising from solid tumors has moved into a new era of patient care and how the field may advance.
Samra Turajlic, MBBS, PhD, on Understanding Metastatic Disease in Renal Cancer and Melanoma
Samra Turajlic, MBBS, PhD, of The Francis Crick Institute, discusses our limited understanding of metastases in terms of the timing of dissemination, the many metastatic phenotypes and varieties of seeding, as well as how the spread of cancer evades the immune system and resists treatment....
Patients of Different Races With Early-Onset Colorectal Cancer Exhibit Distinct Genetic Features
Racial differences in genetic mutations were observed among patients with early-onset colorectal cancer, according to data presented by Andreana N. Holowatyj, PhD, MS, during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract 101). The incidence of early-onset ...
American Cancer Society Names Karen E. Knudsen, MBA, PhD, as Its Next Chief Executive Officer
Karen E. Knudsen, MBA, PhD, will be the next Chief Executive Officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), starting June 1, 2021. She will take the reins from the retiring Gary Reedy, who has served as both...
Cancer and COVID-19: Reflections at 1 Year
We who live and work in Seattle recently took note of two milestones: the first death of a patient from COVID-19 reported in the United States in Seattle on February 28, 2020, and recognition of 5,000 deaths from COVID-19 in the state of Washington on March 2, 2021. The juxtaposition of these two...
Knuckles
The swastikas on his knuckles kept stealing my attention. I tried not to stare but every time he gestured to emphasize his words my gaze snapped back there. That awful symbol, multiplied across all 10 digits, refused to be ignored. The blue lines were blurred and misshapen, probably jail tats. I...
Andrew Ewald, PhD, Named Director of Johns Hopkins Medicine’s Department of Cell Biology
Cancer researcher Andrew Ewald, PhD, has been appointed Director of the Department of Cell Biology at the Johns Hopkins University School of Medicine. He will take over the position from Peter Devreotes, PhD, who will remain on the faculty at Johns Hopkins. Dr. Ewald joined the medical school...
Expert Point of View: Gillianne G.Y. Lai, MBBS
Gillianne G.Y. Lai, MBBS, of the National Cancer Centre, Singapore, discussed the presentations on novel agents for exon 20 insertion mutations in non–small cell lung cancer (NSCLC), which account for about one-third of tyrosine kinase resistance mutations. Although tyrosine kinase mutations are...
Cardiovascular Concerns With the Use of VEGFR Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR) have proved to be effective drugs in the treatment of many solid tumors. However, their clinical benefit may come at the cost of cardiovascular toxicity if clinicians are not vigilant and proactive. During...
Novel Decision-Making Tool for Androgen-Deprivation Therapy for Patients With Prostate Cancer
According to a retrospective study, the combined clinical and cell-cycle risk (CCR) score may be able to accurately predict which patients with intermediate- and high-risk prostate cancer will have little additional benefit from androgen-deprivation therapy added to dose-escalated radiotherapy and...
Ze’ev Ronai, PhD, Named Director of Sanford Burnham Prebys Cancer Center
Sanford Burnham Prebys Medical Discovery Institute has appointed cancer researcher Ze’ev Ronai, PhD, as Director of its National Cancer Institute (NCI)-designated Cancer Center. Established in 1976, the Cancer Center is one of only seven NCI-designated Basic Laboratory Cancer Centers in the...
Expert Point of View: Xin Gao, MD
Xin Gao, MD, a medical oncologist at Mass General Hospital and Instructor at Harvard Medical School, said these were important findings. “Analyses of patient-reported outcomes pertaining to health-related quality-of-life measures from CheckMate 9ER showed significantly improved quality-of-life...
An Oncologist and His Wife Share a Personal Cancer Story
Gastrointestinal oncologist John Marshall, MD, is well known for his candid observations about cancer treatment and research. In 2006, all the scientific intricacies and sociopolitical dramas of oncology coalesced in Dr. Marshall’s life when his 43-year-old wife, Liza, was diagnosed with breast...
Pembrolizumab in First-Line Treatment of Metastatic Clear Cell and Non–Clear Cell Renal Cell Carcinoma
The treatment paradigm for patients with metastatic renal cell carcinoma has undergone a dramatic shift over the past few years, improving outcomes for many patients but leaving many unanswered questions as to how to optimally choose the best treatment for an individual patient. The changes are...
Stand Up To Cancer Announces $3.25 Million in Grants for Head/Neck Cancer Research
Stand Up To Cancer has announced $3.25 million in grants from four national nonprofits to fund research to find new treatments for head and neck cancers, which are newly diagnosed in about 65,000 Americans every year. The grants include contributions of $1.5 million each from the Fanconi Anemia...
How Exceptional Responders Are Providing Clues to Personalizing Cancer Treatment
The findings from a recent study of patients with cancer who had an exceptional response to chemotherapy are yielding new clues on the molecular changes in patients’ tumors. These findings may explain the genetic alterations contributing to these patients’ dramatic and long-lasting responses to...
Cardiovascular Disease in Hematologic Malignancies: Who Is at Risk?
Given the improvements in diagnostic strategies, treatment, and supportive care, long-term survival is now an expected outcome for a large majority of patients with hematologic malignancies. Unfortunately, radiation therapy and anthracyclines, which form the backbone of front-line treatment, have...
Role of Antibody-Drug Conjugates Across Breast Cancer Subtypes
For the treatment of breast cancer, antibody-drug conjugates are emerging as effective players that could impact all subtypes of this disease, according to Kevin Kalinsky, MD, MS, Director of the Glenn Family Breast Cancer at the Winship Cancer Institute of Emory University, Atlanta. In the...
End-of-Life Care Remains Aggressive for Patients With Ovarian Cancer
Patients with ovarian cancer frequently receive aggressive end-of-life care despite industry guidelines that emphasize quality of life for those with advanced disease, according to a recent study published by Mullins et al in the journal Cancer. In fact, by 2016, intensive care unit (ICU) stays and ...
Screening and Education in Melanoma-Prone Families May Improve Early Detection of Disease
Among patients at high risk of melanoma, those who received routine skin cancer screening and education about skin self-exams were significantly more likely to be diagnosed with thinner and earlier-stage melanomas, according to results published by Michael Sargen, MD, and colleagues in Cancer...
Gene Sequencing, Esophageal Brushings May Identify Patients With Barrett’s Esophagus at Risk for Cancer Progression
A combination of esophageal brushing and extensive genetic sequencing of the sample collected may detect chromosome alterations in people with Barrett’s esophagus, identifying patients at risk for progressing to esophageal cancer. These findings were published by Douville et al in ...
